Information Provided By:
Fly News Breaks for April 9, 2018
INCY, NLNK
Apr 9, 2018 | 08:22 EDT
As reported previously, Baird analyst Michael Ulz downgraded NewLink Genetics (NLNK) to Neutral from Outperform. The analyst cited the disappointing results from Incyte's (INCY) Phase-3 ECHO-301 study in melanoma. Given the uncertainty surrounding the opportunity after NewLink said it will revisit the indoximod clinical program following Incyte's news, Ulz lowered his price target to $5 from $22 on NewLink Genetics shares.
News For NLNK;INCY From the Last 2 Days
There are no results for your query NLNK;INCY